These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 11230486

  • 1. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M.
    J Clin Oncol; 2001 Mar 01; 19(5):1414-20. PubMed ID: 11230486
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S.
    Cancer; 2004 Jun 15; 100(12):2583-91. PubMed ID: 15197800
    [Abstract] [Full Text] [Related]

  • 3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.
    Haematologica; 2000 Dec 15; 85(12):1268-70. PubMed ID: 11114133
    [Abstract] [Full Text] [Related]

  • 4. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H.
    J Clin Oncol; 2005 Jun 20; 23(18):4079-88. PubMed ID: 15767648
    [Abstract] [Full Text] [Related]

  • 5. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
    Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, Scheinberg DA, Golde DW.
    Leukemia; 2000 Sep 20; 14(9):1577-82. PubMed ID: 10995003
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 7. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C, Xu W, Xu M, Hong M, Zhu DX, Zhu HY, Wu YJ, Fan L, Qiao C, Zhuang Y, Miao KR, Liu P, Li JY.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan 20; 32(1):3-7. PubMed ID: 21429392
    [Abstract] [Full Text] [Related]

  • 8. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 9. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ.
    J Clin Oncol; 2010 Apr 10; 28(11):1863-9. PubMed ID: 20212251
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia].
    Wang WM, Sun H, Xie XS, Gan SL, Ma P.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb 10; 20(1):70-2. PubMed ID: 22391168
    [Abstract] [Full Text] [Related]

  • 11. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
    Shvidel L, Shtalrid M, Bairey O, Rahimi-Levene N, Lugassy G, Shpilberg O, Polliack A, Berrebi A, Israeli Study Group on CLL.
    Leuk Lymphoma; 2003 Nov 10; 44(11):1947-50. PubMed ID: 14738148
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM.
    Cancer; 2015 Nov 01; 121(21):3869-76. PubMed ID: 26218678
    [Abstract] [Full Text] [Related]

  • 13. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF.
    Cancer; 2006 Jun 01; 106(11):2412-20. PubMed ID: 16649223
    [Abstract] [Full Text] [Related]

  • 14. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P.
    Health Technol Assess; 2017 May 01; 21(28):1-374. PubMed ID: 28628003
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
    Schiavone EM, De Simone M, Palmieri S, Annunziata M, Pocali B, Copia C, D'Amico MR, Vecchio LD, Ferrara F.
    Eur J Haematol; 2003 Jul 01; 71(1):23-8. PubMed ID: 12801295
    [Abstract] [Full Text] [Related]

  • 16. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct 01; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 17. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.
    J Clin Oncol; 2010 Apr 01; 28(10):1756-65. PubMed ID: 20194844
    [Abstract] [Full Text] [Related]

  • 18. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S, Smith AG, Löffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W.
    Lancet; 1996 May 25; 347(9013):1432-8. PubMed ID: 8676625
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E, Kafková A, Fricová M, Guman T, Stecová N.
    Neoplasma; 2003 May 25; 50(6):433-7. PubMed ID: 14689065
    [Abstract] [Full Text] [Related]

  • 20. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E.
    Clin Cancer Res; 2008 Jan 01; 14(1):155-61. PubMed ID: 18172266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.